Amicus Therapeutics (FOLD 5.51%), a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP earnings. The company reported GAAP revenue of $154.7 million, up from$126.7 million (GAAP) a year earlier and $8.0 million ahead of the$146.7 million analyst target. Non-GAAP earnings per share came in at $0.01, far better than the non-GAAP EPS estimate of –$0.12. The quarter showed solid commercial momentum for the co ...